Makhlin I - Search Results

1

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.

Makhlin I, Salinas RD, Zhang D, Jacob F, Ming GL, Song H, Saxena D, Dorsey JF, Nasrallah MP, Morrissette JJ, Binder ZA, O'Rourke DM, Desai AS, Brem S, Bagley SJ. Makhlin I, et al. CNS Oncol. 2019 Nov 1;8(3):CNS43. doi: 10.2217/cns-2019-0014. Epub 2019 Nov 15. CNS Oncol. 2019. PMID: 31769726 Free PMC article. Review.

2

Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.

Makhlin I, Demissei BG, D'Agostino R, Hundley WG, Baleanu-Gogonea C, Wilcox NS, Chen A, Smith AM, O'Connell NS, Januzzi JL, Lesser GJ, Scherrer-Crosbie M, Ibáñez B, Tang WHW, Ky B. Makhlin I, et al. Clin Cancer Res. 2024 Jun 3;30(11):2370-2376. doi: 10.1158/1078-0432.CCR-23-3952. Clin Cancer Res. 2024. PMID: 38573708 Clinical Trial.

3

Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.

Makhlin I, Fox K. Makhlin I, et al. Curr Oncol Rep. 2020 Feb 5;22(2):15. doi: 10.1007/s11912-020-0867-2. Curr Oncol Rep. 2020. PMID: 32025905 Free PMC article. Review.

4

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Clark AS, Makhlin I, DeMichele A. Clark AS, et al. Among authors: makhlin i. Clin Cancer Res. 2021 Jan 15;27(2):371-373. doi: 10.1158/1078-0432.CCR-20-3624. Epub 2020 Nov 3. Clin Cancer Res. 2021. PMID: 33144339 Free PMC article.

5

On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.

Makhlin I, DeMichele A. Makhlin I, et al. Breast Cancer Manag. 2020 Jun;9(2):BMT37. doi: 10.2217/bmt-2020-0005. Epub 2020 Apr 30. Breast Cancer Manag. 2020. PMID: 34475968 Free PMC article. No abstract available.

6

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair IA, Jeschke GR, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman MD, Hexner EO, Bromberg JF, DeMichele A. Makhlin I, et al. NPJ Breast Cancer. 2022 Nov 11;8(1):122. doi: 10.1038/s41523-022-00487-x. NPJ Breast Cancer. 2022. PMID: 36369506 Free PMC article.

7

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.

Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA. Chen S, et al. Among authors: makhlin i. Breast Cancer Res. 2023 Jan 3;25(1):1. doi: 10.1186/s13058-022-01559-3. Breast Cancer Res. 2023. PMID: 36597146 Free PMC article.

8

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.

Makhlin I, DeMichele A. Makhlin I, et al. Cell Rep Med. 2022 Jun 21;3(6):100668. doi: 10.1016/j.xcrm.2022.100668. Cell Rep Med. 2022. PMID: 35732147 Free PMC article.

9

¹⁸F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.

Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Mankoff DA, Clark AS. Makhlin I, et al. Radiol Imaging Cancer. 2022 Nov;4(6):e220032. doi: 10.1148/rycan.220032. Radiol Imaging Cancer. 2022. PMID: 36269154 Free PMC article.

10

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. Makhlin I, et al. BJU Int. 2011 Jul;108(2 Pt 2):E84-90. doi: 10.1111/j.1464-410X.2010.09844.x. Epub 2010 Nov 2. BJU Int. 2011. PMID: 21050361 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters